CeriBell, Inc./$CBLL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CeriBell, Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Ticker
$CBLL
Sector
Primary listing
Employees
281
Headquarters
Website
CeriBell, Inc. Metrics
BasicAdvanced
$463M
-
-$1.81
-
-
Price and volume
Market cap
$463M
52-week high
$25.37
52-week low
$10.01
Average daily volume
276K
Financial strength
Current ratio
13.307
Quick ratio
12.638
Long term debt to equity
11.854
Total debt to equity
12.52
Interest coverage (TTM)
-26.29%
Profitability
EBITDA (TTM)
-50.714
Gross margin (TTM)
87.75%
Net profit margin (TTM)
-63.83%
Operating margin (TTM)
-67.14%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-24.91%
Return on equity (TTM)
-51.39%
Valuation
Price to revenue (TTM)
4.448
Price to book
2.69
Price to tangible book (TTM)
2.69
Price to free cash flow (TTM)
-8.997
Free cash flow yield (TTM)
-11.11%
Free cash flow per share (TTM)
-1.405
Growth
Revenue change (TTM)
42.17%
Earnings per share change (TTM)
-69.92%
Bulls say / Bears say
Total revenue grew 42% year-over-year to $20.5 million in Q1 2025, driven by adoption by new accounts and expansion within the active account base
The FDA granted 510(k) clearance for Ceribell’s Clarity™ algorithm for patients aged 1 and older, making it the first AI-powered EEG system with pediatric seizure detection indication
Ceribell’s point-of-care EEG system received FedRAMP® High authorization—the highest federal cybersecurity designation—positioning it as the only medical device company with this approval for deployment across VA and other federal healthcare systems
Net loss widened to $12.8 million in Q1 2025 from $8.5 million a year earlier, reflecting ongoing unprofitability despite revenue growth
Operating expenses surged 55% to $32.2 million in Q1 2025, outpacing the 42% increase in revenue and putting pressure on profitability
The company remains exposed to supply chain risks and potential tariff impacts, as a substantial number of product components are manufactured and assembled in China, which could erode estimated gross margins
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CeriBell, Inc. stock?
CeriBell, Inc. (CBLL) has a market cap of $463M as of October 05, 2025.
What is the P/E ratio for CeriBell, Inc. stock?
The price to earnings (P/E) ratio for CeriBell, Inc. (CBLL) stock is 0 as of October 05, 2025.
Does CeriBell, Inc. stock pay dividends?
No, CeriBell, Inc. (CBLL) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next CeriBell, Inc. dividend payment date?
CeriBell, Inc. (CBLL) stock does not pay dividends to its shareholders.
What is the beta indicator for CeriBell, Inc.?
CeriBell, Inc. (CBLL) does not currently have a Beta indicator.